Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers.

In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy. PMID: 30092251 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30092251?dopt=Abstract

Source: Antiviral Research - August 6, 2018 Category: Virology Authors: Brodskaia AV, Timin AS, Gorshkov AN, Muslimov AR, Bondarenko AB, Tarakanchikova YV, Zabrodskaya YA, Baranovskaya IL, Il'inskaja EV, Sakhenberg EI, Sukhorukov GB, Vasin AV Tags: Antiviral Res Source Type: research